A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2014
At a glance
- Drugs Tofacitinib (Primary)
- Indications Crohn's disease; Plaque psoriasis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Feb 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 12 Feb 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.